CD274 and neoplasm: Although PD-L1 expression in tumor microenvironment has been explored in several retrospective and prospective clinical trials, across many different tumor types, all the results suggest caution in considering PD-L1 as a reliable method for the selection of eligible patients for immunotherapy (4, 10–14).